Executive Officers

Peter Kolchinsky, Ph.D., 44
Chief Executive Officer and Chairman

Mr. Kolchinsky has served as a Portfolio Manager and Managing Partner of RA Capital Management, L.P. since September 2004. Mr. Kolchinsky is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. He serves as a member of the board of directors of Therapeutics Acquisition Corp., Sojournix, Inc., Freenome Holdings, Inc., Wave Life Sciences Ltd. and Forma Therapeutics Holdings, Inc. He previously served as a member of the board of directors of Synthorx, Inc. and Dicerna Pharmaceuticals, Inc. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of “The Great American Drug Deal” and “The Entrepreneur’s Guide to a Biotech Startup.” He founded the non-profit No Patient Left Behind to advocate for healthcare reforms that would solve affordability and promote continued biomedical innovation. Mr. Kolchinsky holds a B.A. in Biology from Cornell University and a Ph.D. in Virology from Harvard University.

Tess Cameron, 35 [Resigned from Board of Directors 3/29/22]
Chief Financial Officer

Ms. Cameron is a Principal on the Investment Team at RA Capital Management and has been with RA Capital since June 2020. Prior to RA Capital, Ms. Cameron was at Foghorn Therapeutics from January 2018 to May 2020, where she was Head of Finance. Prior to Foghorn, Ms. Cameron held finance leadership roles at Wave Life Sciences Ltd. from January 2017 to January 2018 and at Biogen from March 2014 to January 2017. Prior to joining biotech/pharma, she was a specialist on the corporate finance team at McKinsey & Co. Ms. Cameron has an HBA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada.

Matthew Hammond, Ph.D., 32
Chief Investment Officer and Director

Dr. Hammond is a Principal on the Investment Team at RA Capital Management and has been with RA Capital since December 2014. He works on both public and private healthcare companies. Dr. Hammond serves as a member of the board of directors of Therapeutics Acquisition Corp., Cerebral Therapeutics, Inc., Kira Pharmaceuticals, and DTx Pharma. Dr. Hammond holds a B.S. in Environmental Health Science from the University of Georgia and both a Ph.D. in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. His graduate research investigated innate immune responses after intracerebral hemorrhage.

Board of Directors

Amy Butte, 53
Chairperson Nominee

Ms. Butte has significant experience in leading and advising companies through the initial public offering process as a banker, research analyst, CFO and Board Director. Ms. Butte currently serves on the board of directors of Bain Capital Specialty Finance, Inc., a managed specialty finance company, and Tuscan Holdings Corp., a special purpose acquisition vehicle. Ms. Butte also serves on the board of directors of DigitalOcean Holdings Inc., where she has been audit committee chair since 2018, and BNP Paribas USA, where she has held the role of audit committee chair and a member of the risk management committee since 2016. Ms. Butte is an advisor to several private companies, including the Long-Term Stock Exchange, Inc., a startup marketplace for long-term investors. Ms. Butte was an independent trustee for the Fidelity Investments Strategic Advisors Funds from 2011 to 2017, a board member for Accion International from 2008 to 2014 and the founder of TILE Financial, a Fintech startup, from 2008 to 2012. Previously, Ms. Butte spearheaded two public offerings as Chief Financial Officer, including the public offering of New York Stock Exchange in 2006 and the spin out of Man Financial in 2007.  She also served as Chief Financial Officer and Strategist for the Financial Services Division of Credit Suisse First Boston, Inc. and was a highly ranked equity research analyst at Merrill Lynch & Co. and Bear Stearns & Co., where she took part in multiple capital markets transactions.

Stephen J. Hoffman, M.D., Ph.D., 67
Director 

Dr. Hoffman also currently serves on the Board of Directors of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), Danforth Advisors and is Chairman of the Board of Directors of Apic-Bio, Inc. Dr. Hoffman served as Chief Executive Officer and director of Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) from December 2017 until October 2019. Prior to that, he served as a senior advisor to PDL BioPharma, Inc. from February 2014 until November 2017. Previously he was a managing director at Skyline Ventures, a venture capital firm, from May 2007 until February 2014. From January 2003 to March 2007, Dr. Hoffman was a general partner at TVM Capital, a venture capital firm. From 1994 to 2002, he served as President, Chief Executive Officer and a member of the Board of Directors of Allos Therapeutics, Inc., a biopharmaceutical company, where he remained as Chairman of the Board of Directors until it was acquired by Spectrum Pharmaceuticals, Inc. in September 2012. From 1990 to 1994, Dr. Hoffman completed a fellowship in clinical oncology and a residency/fellowship in dermatology, both at the University of Colorado. Dr. Hoffman was the scientific founder of Somatogen Inc., a biotechnology company that was acquired by Baxter International, Inc. in 1998, where he held the position of Vice President of Science and Technology from 1987 until 1990. Previously, Dr. Hoffman also served on the Boards of Directors of Genocea Biosciences, Inc. (NASDAQ: GNCA), which he resigned from effective April 11, 2017, Sirtris Pharmaceuticals, Inc., a pharmaceutical company that was acquired by GlaxoSmithKline (NYSE: GSK) in 2008 and Palleon Pharmaceuticals, Inc., which he resigned effective November 2020. Dr. Hoffman holds a Ph.D. in bio-organic chemistry from Northwestern University and an M.D. from the University of Colorado School of Medicine.

Thomas Leggett, 44
Director 

Mr. Leggett has served as the chief financial officer of Black Diamond Therapeutics since September 2019. Prior to joining Black Diamond, Mr. Leggett served as Senior Vice President of Finance and Chief Financial Officer at Axcella Health Inc., a biotechnology company, from January 2017 to August 2019. Prior to joining Axcella, Mr. Leggett served as the Treasurer and Head of Business Development Finance at Purdue Pharma L.P., a pharmaceutical company, from May 2016 to December 2017. From November 2009 to April 2016, Mr. Leggett was an Executive Director at UBS Securities LLC, an investment bank, in the Global Healthcare Group with a primary focus in the biopharmaceutical sector. Prior to UBS Securities, Mr. Leggett worked in the Global Healthcare investment banking groups at J.P. Morgan Securities and Lazard Frères & Company. Mr. Leggett holds an M.B.A. in finance from The Wharton School at the University of Pennsylvania and a B.A. in Economics from Columbia University.

Clive Patience, 57
Director 

Dr. Patience has served as an SVP and an EVP of Technical Operations at Agios Pharmaceuticals (Nasdaq: AGIO) since June 2017. He held various management positions at Biogen Idec Inc. (Nasdaq: BIIB) from May 2004 to June 2017. He served as an associate director and a director at Immerge BioTherapeutics Inc. from 2001 to 2004. He was an Emeritus lecturer at Harvard Medical School from 2002 to 2004. He served as scientific officer at Smith Kline Beecham Pharmaceuticals, Gelman Sciences Ltd, Institute of Cancer Research and BioTransplant, Inc. from 1982?–? 2000. Dr. Patience holds a B.Sc. in Microbiology & Immunology from North East Surrey College of Technology and a Ph.D. in Virology from University of London.